KMS-12-PE Cells
€430.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The KMS-12-PE cell line, established from the pleural effusion of the same patient, differs significantly from KMS-12-BM in several aspects. KMS-12-PE cells represent a more terminally differentiated plasma cell stage, as indicated by the absence of CD20 but continued expression of CD38 and PCA-1. A striking feature of KMS-12-PE is its ability to ectopically produce and secrete a salivary type of amylase, both in the patient’s pleural effusion and in culture, making it unique among human myeloma cell lines. This phenomenon is associated with a chromosomal deletion near the region where the amylase gene is located, specifically del(1)(p22→pter), observed in a significant proportion of KMS-12-PE cells. Despite these distinct differences, both KMS-12-PE and KMS-12-BM share the same clonal marker, the translocation t(11;14)(q13;q32), which is common in myeloma cases. However, KMS-12-PE cells show fewer chromosomal abnormalities than KMS-12-BM and tend to be hypodiploid. Like KMS-12-BM, KMS-12-PE does not produce immunoglobulins, either in surface or secretory form, even though the cells have well-developed endoplasmic reticulum. The lack of tumorigenicity in both cell lines, despite their aggressive in vitro growth, and their stable long-term proliferation in serum-free medium make them valuable tools for studying myeloma biology, particularly in the context of non-Ig-producing myeloma. |
|---|---|
| Organism | Human |
| Tissue | Pleural effusion |
| Disease | Multiple Myeloma |
| Synonyms | KMS 12 PE, KMS-12_PE, KMS-12PE, KMS12-PE, KMS12PE, Kawasaki Medical School-12-Pleural Effusion |
Characteristics
| Age | 64 years |
|---|---|
| Gender | Female |
| Ethnicity | Japanese |
| Morphology | Round cells |
| Cell type | B cell |
| Growth properties | Suspension, single cells and small clusters |
Regulatory Data
| Citation | KMS-12-PE (Cytion catalog number 300286) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1333 |
Biomolecular Data
| Surface antigens | CD3 -, CD4 -, CD13 -, CD14 -, CD15 -, CD19 -, CD20 -, CD34 -, CD38 +, CD138 +, HLA-DR +, PCA-1 + |
|---|---|
| Tumorigenic | Not tumorigenic in nude mice |
| Products | No immunoglobulin production |
| Mutational profile | Translocation: t(11;14)(q13;q32) |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Seeding density | 5 x 105 cells/ml |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300286-041024 | Certificate of Analysis | 23. May. 2025 | 300286 |
Material Transfer Agreement
If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.
For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.
Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement.